CytoMed intends to be among early pioneers of cellular immunotherapy treatment modalities in the ASEAN region and North Asia, leveraging Asia's low-cost infrastructure and talents to make affordable GMP-grade immune cells. The company recently completed acquisition of allogeneic gamma delta T cell technology (TCB-002) from TC BioPharm Limited in November 2025, strengthening its platform. CytoMed is located in the heart of a new special economic zone established in early 2025 by Singapore and adjacent State of Johor, Malaysia.
Cyborg Score Rationale
Early-stage clinical company with validated technology (first-in-human trial ongoing since Nov 2024) and strategic geographic positioning. However, minimal cash runway disclosed into 2026, pre-revenue status, and small market cap (~$12.6M) create execution risk. Recent technology acquisition (Nov 2025) and multiple research collaborations demonstrate traction but limited near-term monetization.
Top Insights
First patient safely dosed in November 2024 in the ANGELICA Phase I trial, a first-in-human CAR T trial involving donor-derived allogeneic gamma delta T cells that can recognize multiple cancer types
Acquired Malaysia-licensed cord blood bank in August 2024, providing cost-free raw materials for cord blood-derived therapeutics for autoimmune diseases and cancers
Proprietary gamma delta T cell technology and CAR-γδ T cell technology granted patent by China National Intellectual Property Administration (CNIPA)
Multiple Chinese and international parties have expressed interest in gamma delta T cells program; China and India identified as strategic focus markets
(January 2026) Company issued statement rejecting misleading claims about its research and clinical progress, reaffirming FIH trial status at NUH Singapore
(November 2025) Completed acquisition of TCB-002 allogeneic gamma delta T cell technology from TC BioPharm (Holdings) PLC subsidiary
(November 2024) First patient enrolled in ANGELICA Phase I CAR-γδ T cell trial at National University Hospital Singapore
Open the full interactive CytoMed Therapeutics Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.